Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,000 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the transaction, the director now directly owns 157,557 shares in the company, valued at approximately $14,143,891.89. The trade was a 8.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Blueprint Medicines Trading Up 1.4 %

Shares of NASDAQ BPMC opened at $90.14 on Friday. The firm has a market capitalization of $5.73 billion, a PE ratio of -42.72 and a beta of 0.59. Blueprint Medicines Co. has a one year low of $72.24 and a one year high of $121.90. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The business has a 50-day moving average price of $92.45 and a two-hundred day moving average price of $97.23.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm’s revenue was up 126.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.20) earnings per share. As a group, analysts predict that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Thursday, November 14th. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Monday, December 9th. JPMorgan Chase & Co. began coverage on Blueprint Medicines in a research note on Thursday, November 14th. They set an “overweight” rating and a $126.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th. Finally, Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $122.11.

Institutional Trading of Blueprint Medicines

Several hedge funds and other institutional investors have recently modified their holdings of BPMC. Quarry LP acquired a new position in Blueprint Medicines in the 3rd quarter worth about $32,000. Covestor Ltd lifted its stake in Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 403 shares during the last quarter. Van ECK Associates Corp grew its position in Blueprint Medicines by 13.3% in the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 131 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth $108,000. Finally, Values First Advisors Inc. acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $122,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.